HC Wainwright Has Positive Opinion of TNYA FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Tenaya Therapeutics to a loss of $0.34 per share from a projected loss of $0.37; the consensus estimate is a loss of $0.36.
• Tenaya reported quarterly EPS of a loss of $0.08, beating analyst expectations of a loss of $0.10. Revenue was $1.7 million, versus estimates of $0.8 million.
• Analysts’ overall rating is “Moderate Buy,” with an average price target of $4.00; shares opened at $0.36 and have traded between $0.30 and $1.56 over the past year.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Analysts at HC Wainwright lifted their FY2026 EPS estimates for Tenaya Therapeutics in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.34) for the year, up from their previous forecast of ($0.37). The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Tenaya Therapeutics' Q4 2026 earnings at ($0.08) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.39) EPS.

Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded Tenaya Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Sunday, September 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tenaya Therapeutics in a report on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $4.00.

Tenaya Therapeutics Stock Performance

Shares of TNYA opened at $0.36 on Monday. The business's fifty day simple moving average is $0.54 and its two-hundred day simple moving average is $0.70. Tenaya Therapeutics has a 12 month low of $0.30 and a 12 month high of $1.56. The company has a market cap of $82.10 million, a price-to-earnings ratio of -0.74 and a beta of 2.88.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. The firm had revenue of $1.70 million during the quarter, compared to analysts' expectations of $0.80 million.

Hedge Funds Weigh In On Tenaya Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. R Squared Ltd lifted its holdings in Tenaya Therapeutics by 136.0% during the third quarter. R Squared Ltd now owns 74,350 shares of the company's stock valued at $45,000 after purchasing an additional 42,847 shares in the last quarter. Mirador Capital Partners LP increased its stake in shares of Tenaya Therapeutics by 5.8% in the third quarter. Mirador Capital Partners LP now owns 957,204 shares of the company's stock worth $578,000 after purchasing an additional 52,107 shares in the last quarter. Squarepoint Ops LLC increased its stake in shares of Tenaya Therapeutics by 89.3% in the second quarter. Squarepoint Ops LLC now owns 659,247 shares of the company's stock worth $487,000 after purchasing an additional 310,979 shares in the last quarter. Spark Investment Management LLC bought a new stake in shares of Tenaya Therapeutics during the 2nd quarter valued at $26,000. Finally, Raiffeisen Bank International AG raised its position in shares of Tenaya Therapeutics by 20.0% during the 2nd quarter. Raiffeisen Bank International AG now owns 1,200,000 shares of the company's stock valued at $882,000 after purchasing an additional 200,000 shares during the period. Hedge funds and other institutional investors own 90.54% of the company's stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.

Tenaya's pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.